Uveal melanoma in Israel in the last two decades: Characterization, treatment and prognosis

Israel Medical Association Journal

Volumn 11, Issue 5, 2009, Pages 280-285

  Frenkel, Shahar ^a   Hendler, Karen ^a   Pe'er, Jacob ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Epidemiology; Metastases; Survival; Uveal melanoma

Indexed keywords

IODINE 125; PALLADIUM 103; RUTHENIUM 106;

ADOLESCENT; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; ENUCLEATION; FEMALE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PROGNOSIS; TUMOR LOCALIZATION; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; HUMANS; INCIDENCE; ISRAEL; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 67649240386     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976; 56: 489-91.
2. Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005; 40: 12-17.
3. Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt 2001; 21: 268-71.
4. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol 1978; 62: 420-5.
5. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-93.
6. Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol 2005; 140: 748-9.
7. Pe'er J, Rummelt V, Mawn L, Hwang T, Woolson RF, Folberg R. Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology 1994; 101: 1227-35.
8. Kaiserman I, Anteby I, Chowers I, Blumenthal EZ, Kliers I, Pe'er J. Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy. Ophthalmology 2002; 109: 1137-41.
9. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol (Copenh) 1982; 60: 161-82.
10. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123: 1639-43.
11. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107: 1443-9.
12. Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology 2001; 108: 829-31.
13. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007; 27: 1897-900.
14. Barak V, Frenkel S, Valyi-Nagy K, et al. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker. Invest Ophthalmol Vis Sci 2007; 48: 4399-402.
15. Iscovich J, Ackerman C, Andreev H, Pe'er J, Steinitz R. An epidemiological study of posterior uveal melanoma in Israel, 1961-1989. Int J Cancer 1995; 61: 291-5.
16. Shargal Y, Pe'er J. Uveal malignant melanoma in Israel (1970-1989). Harefuah 1995; 129: 369-74, 448 (Hebrew).
17. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119: 969-82.
18. Hawkins BS. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004; 138: 936-51.
19. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000; 118: 1219-28.
20. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 1998; 125: 745-66.
21. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002; 109: 2197-206.
22. Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol 2004; 137: 893-900.
23. Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 385-91.
24. Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology 2002; 109: 1838-49.
25. Hendler K, Frenkel S, Baruch R, et al. Comparison of serum biomarkers and liver function tests in the early diagnosis of metastases from uveal melanoma [ARVO Abstract]. Invest Ophthalmol Vis Sci 2008; 49: 54.